Literature DB >> 17287965

[Asymptomatic 32 year old female smoker with persistent polyclonal lymphocytosis].

B Chapuy1, G Wulf, H W Tessen, F Griesinger, L Trümper, R Schroers.   

Abstract

A 32 year old female smoker (20 pack years) presented with an asymptomatic lymphocytosis of 13,000/nl and splenomegaly. The patient's blood smear showed an absolute lymphocytosis with 65% atypical lymphocytes. A total of 1% of the lymphocytes were bilobulated. Bone marrow histology and immunphenotyping of blood and bone marrow excluded leukemia and non-Hodgkin's lymphoma. IgH-CDR-3 PCR analysis revealed a polyclonal pattern. In summary, a persistent polyclonal B-cell-lymphocytosis (PPBL) was diagnosed. The exact etiology of PPBL is still unclear, however, it is associated with a polyclonal raise in the lymphocyte count of CD27+IgD+-memory-B-lymphocytes due to a defect in apoptosis signaling and leukocyte homing to secondary lymphoid tissues. An association with cigarette smoking is obvious since all patients are smokers. From all published cases, only two developed a malignancy with an uncertain association with PPBL. We have been monitoring our patient for 6.5 years without any evidence of the development of a lymphoma.

Entities:  

Mesh:

Year:  2007        PMID: 17287965     DOI: 10.1007/s00108-007-1800-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  17 in total

1.  Distinct chromosome 3 abnormalities in persistent polyclonal B-cell lymphocytosis.

Authors:  E Callet-Bauchu; S Gazzo; C Poncet; J Pagès; D Morel; C Alliot; B Coiffier; P Coeur; G Salles; P Felman
Journal:  Genes Chromosomes Cancer       Date:  1999-11       Impact factor: 5.006

2.  Familial persistent polyclonal B-cell lymphocytosis.

Authors:  A Himmelmann; R Rüegg; J Fehr
Journal:  Leuk Lymphoma       Date:  2001-03

3.  Persistent polyclonal B lymphocytosis: morphological, immunological, cytogenetic and molecular analysis of an Italian case.

Authors:  S Tonelli; P Vanzanelli; S Sacchi; C Fiorani; I Castelli; P Temperani; G Bonacorsi
Journal:  Leuk Res       Date:  2000-10       Impact factor: 3.156

Review 4.  Chronic B-cell lymphocytosis with binucleated lymphocytes (LWBL): a review of 38 cases.

Authors:  X Troussard; G Flandrin
Journal:  Leuk Lymphoma       Date:  1996-01

5.  Persistent polyclonal B-cell lymphocytosis--an important differential diagnosis of B-cell chronic lymphocytic leukemia.

Authors:  P Reimer; F Weissinger; H P Tony; K H Koniczek; M Wilhelm
Journal:  Ann Hematol       Date:  2000-06       Impact factor: 3.673

6.  Persistent polyclonal B-cell lymphocytosis: further evidence for a genetic disorder associated with B-cell abnormalities.

Authors:  R Delage; L Jacques; M Massinga-Loembe; J Poulin; D Bilodeau; C Mignault; P F Leblond; A Darveau
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

7.  Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR.

Authors:  M Brüggemann; J Droese; I Bolz; P Lüth; C Pott; N von Neuhoff; U Scheuering; M Kneba
Journal:  Leukemia       Date:  2000-08       Impact factor: 11.528

8.  Intravascular bone marrow accumulation in persistent polyclonal lymphocytosis: a misleading feature for B-cell neoplasm.

Authors:  Pierre Feugier; Anne Kennel De March; Jean F Lesesve; Nathalie Monhoven; Véronique Dorvaux; Françoise Braun; Marie J Grégoire; Philippe Jonveaux; Pierre Lederlin; Marie C Béné; Eric Labouyrie
Journal:  Mod Pathol       Date:  2004-09       Impact factor: 7.842

Review 9.  [Persistent polyclonal B-cell lymphocytosis].

Authors:  U Schönermarck; H Diem; P Lohse; W Samtleben
Journal:  Dtsch Med Wochenschr       Date:  2003-05-16       Impact factor: 0.628

10.  Persistent polyclonal B lymphocytosis with Epstein-Barr virus antibodies and subsequent malignant pulmonary blastoma.

Authors:  E Lawlor; M Murray; D S O'Briain; C Blaney; L Foroni; P Sarsfield; D Condell; F Sullivan; S R McCann
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.